Cassava Sciences的理查德·巴里（Richard Barry）将接任永久首席执行官

Cassava Sciences (NASDAQ:SAVA) has concluded its search for a new chief executive officer and named Richard Barry, who has been serving as interim CEO since July, to the post permanently.

The pharma firm, which is focused on neuroscience, initiated a search for a new permanent CEO to replace Remi Barbier, who resigned from the company and the board in July. It had named Richard Barry as its principal executive officer and executive chairman of the board at the time.

In line with its pledge to follow good governance principles, Cassava Sciences (SAVA) is also separating the positions of CEO and chairman by appointing Claude Nicaise as its chairman. Dr. Nicaise has served as a director of Cassava (SAVA) since December 2023.

Shares of Cassava Sciences (SAVA) were marginally up premarket, but has gained 20% year-to-date.

More on Cassava Sciences

• Cassava Sciences: Volatility Provides Trading Opportunities
• Cassava Sciences: New CEO, Same Old Problems
• Cassava Sciences Q2 Earnings Review: So Many Questions, So Few Answers
• Cassava Sciences down 15% following $40M loss contingency to resolve SEC probe
• Cassava Sciences extends Alzheimer’s drug trials by up to 36 months